Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $11.27 in the prior trading day, Roivant Sciences Ltd (NASDAQ: ROIV) closed at $10.94, down -2.93%. In other words, the price has decreased by -$2.93 from its previous closing price. On the day, 14.0 million shares were traded. ROIV stock price reached its highest trading level at $11.32 during the session, while it also had its lowest trading level at $10.92.
Ratios:
Our goal is to gain a better understanding of ROIV by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 33.47 and its Current Ratio is at 33.47. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on February 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $17.
On January 05, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $20.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $14.Deutsche Bank initiated its Buy rating on December 12, 2023, with a $14 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 20 ’25 when Venker Eric sold 100,000 shares for $11.45 per share. The transaction valued at 1,145,000 led to the insider holds 1,462,223 shares of the business.
Ramaswamy Vivek sold 577,007 shares of ROIV for $6,612,500 on Jun 20 ’25. The 10% Owner now owns 37,284,108 shares after completing the transaction at $11.46 per share. On Jun 18 ’25, another insider, Ramaswamy Vivek, who serves as the 10% Owner of the company, sold 565,266 shares for $11.45 each. As a result, the insider received 6,472,296 and left with 37,861,115 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 7437077504 and an Enterprise Value of 3374286336. For the stock, the TTM Price-to-Sale (P/S) ratio is 97.61 while its Price-to-Book (P/B) ratio in mrq is 1.62. Its current Enterprise Value per Revenue stands at 116.142 whereas that against EBITDA is -3.146.
Stock Price History:
The Beta on a monthly basis for ROIV is 1.15, which has changed by 0.0438931 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, ROIV has reached a high of $13.06, while it has fallen to a 52-week low of $8.73. The 50-Day Moving Average of the stock is -1.51%, while the 200-Day Moving Average is calculated to be -2.43%.
Shares Statistics:
The stock has traded on average 6.57M shares per day over the past 3-months and 8985240 shares per day over the last 10 days, according to various share statistics. A total of 695.94M shares are outstanding, with a floating share count of 419.13M. Insiders hold about 38.35% of the company’s shares, while institutions hold 71.09% stake in the company. Shares short for ROIV as of 1749772800 were 45062132 with a Short Ratio of 6.86, compared to 1747267200 on 49232094. Therefore, it implies a Short% of Shares Outstanding of 45062132 and a Short% of Float of 9.0500005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The company has 3.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.2 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$0.81 and -$1.22 for the fiscal current year, implying an average EPS of -$1.01. EPS for the following year is -$1.25, with 4.0 analysts recommending between -$1.06 and -$1.4.
Revenue Estimates
5 analysts predict $7.16M in revenue for the current quarter. It ranges from a high estimate of $15M to a low estimate of $1.78M. As of the current estimate, Roivant Sciences Ltd’s year-ago sales were $55.13MFor the next quarter, 5 analysts are estimating revenue of $7.26M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $1.78M.
A total of 6 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $60M, while the lowest revenue estimate was $7.12M, resulting in an average revenue estimate of $29.24M. In the same quarter a year ago, actual revenue was $29.05MBased on 6 analysts’ estimates, the company’s revenue will be $43.54M in the next fiscal year. The high estimate is $112M and the low estimate is $20M.
